Breaking News Instant updates and real-time market news.

ALIOF

Actelion

, JNJ

Johnson & Johnson

$134.35

1.31 (0.98%)

17:08
06/18/17
06/18
17:08
06/18/17
17:08

Actelion granted Orphan designation for macitentan

The FDA granted Actelion (ALIOF) Orphan designation for its macitentan product in the treatment of chronic thromboembolic pulmonary hypertension. The designation was granted June 15, according to an online notice from the agency. Actelion has been acquired by Johnson & Johnson (JNJ). Reference Link

ALIOF

Actelion

JNJ

Johnson & Johnson

$134.35

1.31 (0.98%)

ALIOF Actelion

01/26/17
01/26/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cognex (CGNX) initiated with a Neutral at JPMorgan. 2. Realogy (RLGY) initiated with a Hold at Deutsche Bank. 3. EQT Midstream Partners (EQM) ande EQT GP (EQGP) were initiated with a Buy at Janney Capital. 4. Williams (WMB) was assumed with an Outperform at Credit Suisse, while Williams Partners (WPZ) was assumed with a Neutral. 5. Actelion (ALIOF) reinstated with a Hold at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/31/17
01/31/17
NO CHANGE

Deutsche sees label warnings as worst case for Actelion drug
After France's National Agency for the Safety of Medicines and Health Products, in a letter dated January 24, asked doctors to stop treating new patients with Actelion's (ALIOF) Uptravi as it investigates patient deaths, Deutsche Bank said it believes a label warnings for the pulmonary arterial hypertension drug is likely the worst case scenario. The firm thinks Johnson & Johnson (JNJ) likely knew of the letter before reaching an agreement to acquire Actelion. Shares of Actelion are down 4% to $65.40 in morning trading.
03/08/17
JPMS
03/08/17
UPGRADE
JPMS
Overweight
Actelion upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Gordon upgraded Actelion (ALIOF) to Overweight citing a "high confidence" that the Johnson & Johnson (JNJ) buyout will complete. The analyst sees 7% potential return by mid-2017.
04/19/17
UBSW
04/19/17
NO CHANGE
Target $136
UBSW
Buy
Johnson & Johnson weakness a buying opportunity, says UBS
UBS analyst Matt Miksic believes Johnson & Johnson (JNJ) delivered a solid bottom line beat on in-line sales but prior period adjustments impacted Pharma growth, making the as-reported results look less robust. He raised his estimates to include the Actelion (ALIOF), deal which is expected to close in Q2. Miksic views the initial pullback in the stock as creating a particularly attractive entry point for investors. Miksic reiterated his Buy rating and $136 price target on Johnson & Johnson shares.
JNJ Johnson & Johnson
$134.35

1.31 (0.98%)

06/07/17
FBCO
06/07/17
NO CHANGE
Target $38
FBCO
Outperform
ASCO meeting highlights pressure on Pfizer cancer assets, says Credit Suisse
Credit Suisse analyst Vamil Divan said he came away from the ASCO meeting feeling like positive progress by competitors is increasing the pressure on Pfizer's (PFE) cancer assets, specifically pointing to positive data for Roche's (RHHBY) Alecensa, Johnson & Johnson's (JNJ) Zytiga and Eli Lilly's (LLY) abemaciclib. Additionally, competition in the immune-oncology and PARP spaces will make it more challenging for Pfizer to gain traction, added Divan. He keeps an Outperform rating on Pfizer, citing valuation and its dividend yield, but he has concerns about its upcoming patent expirations and growth products.
06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Tesaro prostate study suspension due to fast enrollment, says Credit Suisse
After speaking to Tesaro (TSRO), after they spoke to their partner Johnson & Johnson (JNJ), Credit Suisse analyst Alethia Young said the news of the companies' suspension of participant recruitment in the study of niraparib in prostate cancer is actually positive, since it is due to the trial enrolling faster than expected. The suspension has nothing to do with safety or efficacy and is not a clinical hold, but is due to having too many patients in the first part of trial, Young was told. She maintains an Outperform rating on Tesaro shares.
06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
Misunderstanding creates buying opportunity in Tesaro stock, says SunTrust
SunTrust analyst Peter Lawson says that the suspension of participant recruitment by Johnson & Johnson (JNJ) for a study of Tesaro's (TSRO) PARP inhibitor Zejula in prostate cancer "is being incorrectly viewed as a clinical hold." After speaking with J&J, Lawson says that the suspension was not due to clinical or safety issues, but to overly fast enrollment. The analyst says that the early data on PARP inhibitors in prostate cancer has been "encouraging." He believes that the misunderstanding has created a buying opportunity in Tesaro stock. .
06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Eli Lilly has positive read through from J&J data, says SunTrust
SunTrust analyst John Boris says that data for Johnson & Johnson's (JNJ) Invokana for diabetes represented a best-case scenario for Eli Lilly (LLY). J&J's drug "significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke in diabetes patients at risk for or with a history of CV diseases," and its efficacy on CV death is positive for the SGLT-2 class, to which Eli Lilly's Jardiance also belongs, according to the analyst. But the data leaves Jardiance, which reduced CV death by a statistically significant 38% versus Invokana's non-significant 13%, as the best in the class, wrote the analyst, who reiterates a $101 price target and a Buy rating on Eli Lilly.

TODAY'S FREE FLY STORIES

LNDC

Landec

$12.55

0.6 (5.02%)

16:10
09/26/17
09/26
16:10
09/26/17
16:10
Earnings
Landec sees Q2 EPS 6c-8c, consensus 10c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

WLKP

Westlake Chemical Partners

$24.00

0.05 (0.21%)

16:10
09/26/17
09/26
16:10
09/26/17
16:10
Syndicate
Westlake Chemical Partners files to sell 4.5M units for limited partners »

UBS Investment Bank,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLKP

Westlake Chemical Partners

$24.00

0.05 (0.21%)

16:09
09/26/17
09/26
16:09
09/26/17
16:09
Hot Stocks
Westlake Chemical Partners to acquire extra 5% interest in OpCo »

Westlake Chemical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNDC

Landec

$12.55

0.6 (5.02%)

16:08
09/26/17
09/26
16:08
09/26/17
16:08
Earnings
Landec reports Q1 EPS 8c, consensus 6c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

MU

Micron

$34.18

-0.69 (-1.98%)

16:08
09/26/17
09/26
16:08
09/26/17
16:08
Technical Analysis
Technical View: Micron spikes higher after earnings beat »

In the extended session…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MU

Micron

$34.18

-0.69 (-1.98%)

16:07
09/26/17
09/26
16:07
09/26/17
16:07
Hot Stocks
Micron CEO expects healthy industry fundamentals to continue into 2018 »

"Micron delivered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AMSC

AMSC

$4.03

0.01 (0.25%)

16:06
09/26/17
09/26
16:06
09/26/17
16:06
Hot Stocks
AMSC completes acquisition of Infinia Technology »

AMSC announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

16:06
09/26/17
09/26
16:06
09/26/17
16:06
Hot Stocks
Micron says Q4 margin increase due to DRAM products »

Revenues for the fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

GFF

Griffon

$21.55

0.55 (2.62%)

, EMR

Emerson

$63.13

-0.48 (-0.75%)

16:06
09/26/17
09/26
16:06
09/26/17
16:06
Hot Stocks
Griffon amends ClosetMaid purchase agreement »

Griffon Corporation (GFF)…

GFF

Griffon

$21.55

0.55 (2.62%)

EMR

Emerson

$63.13

-0.48 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AVGR

Avinger

$0.21

-0.0211 (-9.13%)

16:04
09/26/17
09/26
16:04
09/26/17
16:04
Hot Stocks
Avinger receives CE Marking approval for in-stent restenosis treatment »

Avinger announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLBD

Blue Bird

$18.85

0.2 (1.07%)

16:03
09/26/17
09/26
16:03
09/26/17
16:03
Hot Stocks
Blue Bird enters stock repurchase agreement with Coliseum Capital »

Blue Bird Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

AMGN

Amgen

$185.60

-0.69 (-0.37%)

, SCR

Simcere

16:03
09/26/17
09/26
16:03
09/26/17
16:03
Hot Stocks
Amgen and Simcere execute agreement to co-develop four biosimilars in China »

Amgen (AMGN) and Simcere…

AMGN

Amgen

$185.60

-0.69 (-0.37%)

SCR

Simcere

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

ITCI

Intra-Cellular

16:02
09/26/17
09/26
16:02
09/26/17
16:02
Syndicate
Intra-Cellular files to sell $150M in common stock »

J. P. Morgan Securities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MU

Micron

16:01
09/26/17
09/26
16:01
09/26/17
16:01
Earnings
Micron reports Q4 EPS $2.02 , consensus $1.84 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

SIEGY

Siemens

$68.96

-0.81 (-1.16%)

, ALSMY

Alstom

$3.91

-0.045 (-1.14%)

15:58
09/26/17
09/26
15:58
09/26/17
15:58
Hot Stocks
Siemens, Alstom confirm agreement to combine mobility businesses »

Siemens (SIEGY) and…

SIEGY

Siemens

$68.96

-0.81 (-1.16%)

ALSMY

Alstom

$3.91

-0.045 (-1.14%)

GE

General Electric

$24.97

-0.145 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

HII

Huntington Ingalls

$222.73

2.25 (1.02%)

15:50
09/26/17
09/26
15:50
09/26/17
15:50
Hot Stocks
Huntington Ingalls partners with Ivis to develop compliance software »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$40.93

-1.44 (-3.40%)

15:50
09/26/17
09/26
15:50
09/26/17
15:50
Options
JD options volume is 2.5X daily average and calls outpace puts 4:1 »

JD options volume is 2.5X…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$171.00

-8 (-4.47%)

, INTC

Intel

$37.16

-0.02 (-0.05%)

15:42
09/26/17
09/26
15:42
09/26/17
15:42
Periodicals
Breaking Periodicals news story on Nvidia, Intel, Tesla »

Tesla shifting from…

NVDA

Nvidia

$171.00

-8 (-4.47%)

INTC

Intel

$37.16

-0.02 (-0.05%)

TSLA

Tesla

$344.99

-6.1 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 05

    Oct

  • 08

    Oct

  • 22

    Oct

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

, TWLO

Twilio

$28.86

-0.615 (-2.09%)

15:38
09/26/17
09/26
15:38
09/26/17
15:38
Hot Stocks
Amazon discussses launch of AWS Global SMS two-way text messaging »

Amazon's (AMZN)…

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

TWLO

Twilio

$28.86

-0.615 (-2.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 08

    Oct

  • 22

    Oct

LNDC

Landec

$11.95

-0.3 (-2.45%)

15:34
09/26/17
09/26
15:34
09/26/17
15:34
Options
Landec options imply 12.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

T

AT&T

$38.80

-0.32 (-0.82%)

15:30
09/26/17
09/26
15:30
09/26/17
15:30
Periodicals
AT&T's DirecTV to allow 'some' refunds after anthem strife, WSJ says »

Certain subscribers to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Nov

AMJ

American Medical Laboratories Inc

$28.50

0.01 (0.04%)

15:30
09/26/17
09/26
15:30
09/26/17
15:30
Options
Alerian MLP attracts a bullish option play »

Alerian MLP attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$85.47

-1.105 (-1.28%)

15:27
09/26/17
09/26
15:27
09/26/17
15:27
Hot Stocks
AbbVie says will take one single digit price increase for 2018 »

AbbVie issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 08

    Nov

STZ

Constellation Brands, also tag STZ.B

$200.37

-0.24 (-0.12%)

15:25
09/26/17
09/26
15:25
09/26/17
15:25
Options
Constellation Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

$NSD

NASDAQ Market Internals

15:17
09/26/17
09/26
15:17
09/26/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.